Canada markets close in 4 hours 21 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
283.55+0.26 (+0.09%)
As of 11:39AM EST. Market open.
Full screen
Loading interactive chart...
  • Simply Wall St.

    Those who invested in Amgen (NASDAQ:AMGN) five years ago are up 86%

    When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...

  • Reuters

    UPDATE 1-Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients

    Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday. The company expects the largest advantage in patients with lower levels of PDL1, the protein targeted by Keytruda, and plans to launch a phase-three trial enrolling only those patients soon, Mirati chief executive officer David Meek told Reuters.

  • Reuters

    Amgen says experimental obesity drug has promising durability

    Amgen Inc's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday. The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%.